Last reviewed · How we verify
Oral administration of Ipragliflozin
Oral administration of Ipragliflozin is a SGLT2 inhibitor Small molecule drug developed by Asan Medical Center. It is currently FDA-approved for Type 2 diabetes mellitus.
Ipragliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels.
Ipragliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Oral administration of Ipragliflozin |
|---|---|
| Sponsor | Asan Medical Center |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
As an SGLT2 inhibitor, ipragliflozin blocks the SGLT2 transporter on the proximal tubule of the nephron, preventing the reabsorption of filtered glucose. This leads to increased urinary glucose excretion (glucosuria) and a reduction in blood glucose levels independent of insulin secretion. The mechanism also provides cardiovascular and renal protective benefits beyond glycemic control.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Polydipsia
- Diabetic ketoacidosis
Key clinical trials
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients (PHASE3)
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients (PHASE3)
- A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients (PHASE3)
- A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus (PHASE2)
- Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy (PHASE4)
- A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus (PHASE3)
- A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (PHASE3)
- A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral administration of Ipragliflozin CI brief — competitive landscape report
- Oral administration of Ipragliflozin updates RSS · CI watch RSS
- Asan Medical Center portfolio CI
Frequently asked questions about Oral administration of Ipragliflozin
What is Oral administration of Ipragliflozin?
How does Oral administration of Ipragliflozin work?
What is Oral administration of Ipragliflozin used for?
Who makes Oral administration of Ipragliflozin?
What drug class is Oral administration of Ipragliflozin in?
What development phase is Oral administration of Ipragliflozin in?
What are the side effects of Oral administration of Ipragliflozin?
What does Oral administration of Ipragliflozin target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2 (sodium-glucose cotransporter 2)
- Manufacturer: Asan Medical Center — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: Oral administration of Ipragliflozin vs similar drugs
- Pricing: Oral administration of Ipragliflozin cost, discount & access